NBS $2 12 MONTH TARGET SEE HERE PLAYAZZZ Invest
Post# of 25327
[b]NBS >> $2 12 MONTH TARGET SEE HERE PLAYAZZZ[/b]
Investment Highlights
Divested ownership interest in Suzhou Erye Pharmaceutical Co, increasing its cash position by $12,280,000 - Already received $1,228,000 (10%)
Acute Myocardial Infarction (AMI) therapeutic product development team enrolled the first patient in the PreSERVE Phase 2 clinical trial
Our Progenitor Cell Therapy (PCT) CDMO service business continues to grow and has added new clients in later stage clinical trials setting the stage for expansion into larger and substantially more lucrative commercial manufacturing contracts
Jonathan Sackner-Bernstein, MD, FACC joined the Company. He was Associate Center Director for Technology and Innovation at the U.S. Food and Drug Administration's Center for Devices and Radiological Health
Actively pursuing additional strategic relationships with major pharmaceutical and biotechnology companies in 2012
WBB Securities LLC - UPGRADED TO STRONG BUY - $2.00 12 MONTH TARGET
(0)
(0)